Diuretic resistance predicts mortality in patients with advanced heart failure

Gerald W. Neuberg, Alan B. Miller, Chris M. O'Connor, Robert N. Belkin, Peter E. Carson, Anne B. Cropp, David J. Frid, Regina G. Nye, Milton L. Pressler, John H. Wertheimer, Milton Packer

Research output: Contribution to journalArticle

247 Citations (Scopus)

Abstract

Background: In patients with chronic heart failure (CHF), diuretic requirements increase as the disease progresses. Because diuretic resistance can be overcome with escalating doses, the evaluation of CHF severity and prognosis may be incomplete without considering the intensity of therapy. Methods: The prognostic importance of diuretic resistance (as evidenced by a high-dose requirement) was retrospectively evaluated in 1153 patients with advanced CHF who were enrolled in the Prospective Randomized Amlodipine Survival Evaluation (PRAISE). The relation of loop diuretic and angiotensin-converting enzyme inhibitor doses (defined by their median values) and other baseline characteristics to total and cause-specific mortality was determined by proportion hazards regression. Results: High diuretic doses were independently associated with mortality, sudden death, and pump failure death (adjusted hazard ratios [HRs] 1.37 [P = .004], 1.39 [P = .042], and 1.51 [P = .034], respectively). Use of metolazone was an independent predictor of total mortality (adjusted HR = 1.37, P = .016) but not of cause-specific mortality. Low angiotensin-converting enzyme inhibitor dose was an independent predictor of pump failure death (adjusted HR = 2.21, P = .0005). Unadjusted mortality risks of congestion and its treatment were additive and comparable to those of established risk factors. Conclusions: The independent association of high diuretic doses with mortality suggests that diuretic resistance should be considered an indicator of prognosis in patients with chronic CHF. These retrospective observations do not establish harm or rule out a long-term benefit of diuretics in CHF, because selection bias may entirely explain the relation of prescribed therapy to death.

Original languageEnglish (US)
Pages (from-to)31-38
Number of pages8
JournalAmerican Heart Journal
Volume144
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Diuretics
Heart Failure
Mortality
Angiotensin-Converting Enzyme Inhibitors
Metolazone
Sodium Potassium Chloride Symporter Inhibitors
Amlodipine
Selection Bias
Sudden Death
Therapeutics
Survival

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Neuberg, G. W., Miller, A. B., O'Connor, C. M., Belkin, R. N., Carson, P. E., Cropp, A. B., ... Packer, M. (2002). Diuretic resistance predicts mortality in patients with advanced heart failure. American Heart Journal, 144(1), 31-38. https://doi.org/10.1067/mhj.2002.123144

Diuretic resistance predicts mortality in patients with advanced heart failure. / Neuberg, Gerald W.; Miller, Alan B.; O'Connor, Chris M.; Belkin, Robert N.; Carson, Peter E.; Cropp, Anne B.; Frid, David J.; Nye, Regina G.; Pressler, Milton L.; Wertheimer, John H.; Packer, Milton.

In: American Heart Journal, Vol. 144, No. 1, 2002, p. 31-38.

Research output: Contribution to journalArticle

Neuberg, GW, Miller, AB, O'Connor, CM, Belkin, RN, Carson, PE, Cropp, AB, Frid, DJ, Nye, RG, Pressler, ML, Wertheimer, JH & Packer, M 2002, 'Diuretic resistance predicts mortality in patients with advanced heart failure', American Heart Journal, vol. 144, no. 1, pp. 31-38. https://doi.org/10.1067/mhj.2002.123144
Neuberg GW, Miller AB, O'Connor CM, Belkin RN, Carson PE, Cropp AB et al. Diuretic resistance predicts mortality in patients with advanced heart failure. American Heart Journal. 2002;144(1):31-38. https://doi.org/10.1067/mhj.2002.123144
Neuberg, Gerald W. ; Miller, Alan B. ; O'Connor, Chris M. ; Belkin, Robert N. ; Carson, Peter E. ; Cropp, Anne B. ; Frid, David J. ; Nye, Regina G. ; Pressler, Milton L. ; Wertheimer, John H. ; Packer, Milton. / Diuretic resistance predicts mortality in patients with advanced heart failure. In: American Heart Journal. 2002 ; Vol. 144, No. 1. pp. 31-38.
@article{f0d93403d5004e859268e18945371f90,
title = "Diuretic resistance predicts mortality in patients with advanced heart failure",
abstract = "Background: In patients with chronic heart failure (CHF), diuretic requirements increase as the disease progresses. Because diuretic resistance can be overcome with escalating doses, the evaluation of CHF severity and prognosis may be incomplete without considering the intensity of therapy. Methods: The prognostic importance of diuretic resistance (as evidenced by a high-dose requirement) was retrospectively evaluated in 1153 patients with advanced CHF who were enrolled in the Prospective Randomized Amlodipine Survival Evaluation (PRAISE). The relation of loop diuretic and angiotensin-converting enzyme inhibitor doses (defined by their median values) and other baseline characteristics to total and cause-specific mortality was determined by proportion hazards regression. Results: High diuretic doses were independently associated with mortality, sudden death, and pump failure death (adjusted hazard ratios [HRs] 1.37 [P = .004], 1.39 [P = .042], and 1.51 [P = .034], respectively). Use of metolazone was an independent predictor of total mortality (adjusted HR = 1.37, P = .016) but not of cause-specific mortality. Low angiotensin-converting enzyme inhibitor dose was an independent predictor of pump failure death (adjusted HR = 2.21, P = .0005). Unadjusted mortality risks of congestion and its treatment were additive and comparable to those of established risk factors. Conclusions: The independent association of high diuretic doses with mortality suggests that diuretic resistance should be considered an indicator of prognosis in patients with chronic CHF. These retrospective observations do not establish harm or rule out a long-term benefit of diuretics in CHF, because selection bias may entirely explain the relation of prescribed therapy to death.",
author = "Neuberg, {Gerald W.} and Miller, {Alan B.} and O'Connor, {Chris M.} and Belkin, {Robert N.} and Carson, {Peter E.} and Cropp, {Anne B.} and Frid, {David J.} and Nye, {Regina G.} and Pressler, {Milton L.} and Wertheimer, {John H.} and Milton Packer",
year = "2002",
doi = "10.1067/mhj.2002.123144",
language = "English (US)",
volume = "144",
pages = "31--38",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Diuretic resistance predicts mortality in patients with advanced heart failure

AU - Neuberg, Gerald W.

AU - Miller, Alan B.

AU - O'Connor, Chris M.

AU - Belkin, Robert N.

AU - Carson, Peter E.

AU - Cropp, Anne B.

AU - Frid, David J.

AU - Nye, Regina G.

AU - Pressler, Milton L.

AU - Wertheimer, John H.

AU - Packer, Milton

PY - 2002

Y1 - 2002

N2 - Background: In patients with chronic heart failure (CHF), diuretic requirements increase as the disease progresses. Because diuretic resistance can be overcome with escalating doses, the evaluation of CHF severity and prognosis may be incomplete without considering the intensity of therapy. Methods: The prognostic importance of diuretic resistance (as evidenced by a high-dose requirement) was retrospectively evaluated in 1153 patients with advanced CHF who were enrolled in the Prospective Randomized Amlodipine Survival Evaluation (PRAISE). The relation of loop diuretic and angiotensin-converting enzyme inhibitor doses (defined by their median values) and other baseline characteristics to total and cause-specific mortality was determined by proportion hazards regression. Results: High diuretic doses were independently associated with mortality, sudden death, and pump failure death (adjusted hazard ratios [HRs] 1.37 [P = .004], 1.39 [P = .042], and 1.51 [P = .034], respectively). Use of metolazone was an independent predictor of total mortality (adjusted HR = 1.37, P = .016) but not of cause-specific mortality. Low angiotensin-converting enzyme inhibitor dose was an independent predictor of pump failure death (adjusted HR = 2.21, P = .0005). Unadjusted mortality risks of congestion and its treatment were additive and comparable to those of established risk factors. Conclusions: The independent association of high diuretic doses with mortality suggests that diuretic resistance should be considered an indicator of prognosis in patients with chronic CHF. These retrospective observations do not establish harm or rule out a long-term benefit of diuretics in CHF, because selection bias may entirely explain the relation of prescribed therapy to death.

AB - Background: In patients with chronic heart failure (CHF), diuretic requirements increase as the disease progresses. Because diuretic resistance can be overcome with escalating doses, the evaluation of CHF severity and prognosis may be incomplete without considering the intensity of therapy. Methods: The prognostic importance of diuretic resistance (as evidenced by a high-dose requirement) was retrospectively evaluated in 1153 patients with advanced CHF who were enrolled in the Prospective Randomized Amlodipine Survival Evaluation (PRAISE). The relation of loop diuretic and angiotensin-converting enzyme inhibitor doses (defined by their median values) and other baseline characteristics to total and cause-specific mortality was determined by proportion hazards regression. Results: High diuretic doses were independently associated with mortality, sudden death, and pump failure death (adjusted hazard ratios [HRs] 1.37 [P = .004], 1.39 [P = .042], and 1.51 [P = .034], respectively). Use of metolazone was an independent predictor of total mortality (adjusted HR = 1.37, P = .016) but not of cause-specific mortality. Low angiotensin-converting enzyme inhibitor dose was an independent predictor of pump failure death (adjusted HR = 2.21, P = .0005). Unadjusted mortality risks of congestion and its treatment were additive and comparable to those of established risk factors. Conclusions: The independent association of high diuretic doses with mortality suggests that diuretic resistance should be considered an indicator of prognosis in patients with chronic CHF. These retrospective observations do not establish harm or rule out a long-term benefit of diuretics in CHF, because selection bias may entirely explain the relation of prescribed therapy to death.

UR - http://www.scopus.com/inward/record.url?scp=0036301903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036301903&partnerID=8YFLogxK

U2 - 10.1067/mhj.2002.123144

DO - 10.1067/mhj.2002.123144

M3 - Article

C2 - 12094185

AN - SCOPUS:0036301903

VL - 144

SP - 31

EP - 38

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 1

ER -